Advance Search
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
AN Jing, LAO Yun-fei, TANG Song-yuan. Incidence of low-level viraemia among HIV/AIDS patients with antiviral therapy in Yunnan province, 2004 – 2018: a retrospective analysis[J]. Chinese Journal of Public Health, 2022, 38(7): 908-913. doi: 10.11847/zgggws1132975
Citation: AN Jing, LAO Yun-fei, TANG Song-yuan. Incidence of low-level viraemia among HIV/AIDS patients with antiviral therapy in Yunnan province, 2004 – 2018: a retrospective analysis[J]. Chinese Journal of Public Health, 2022, 38(7): 908-913. doi: 10.11847/zgggws1132975

Incidence of low-level viraemia among HIV/AIDS patients with antiviral therapy in Yunnan province, 2004 – 2018: a retrospective analysis

doi: 10.11847/zgggws1132975
  • Received Date: 2020-11-02
    Available Online: 2021-12-13
  • Publish Date: 2022-07-01
  •   Objective  To examine general situation and change trend of low-level viraemia (LLV) among human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients under antiviral therapy (ART) in Yunnan province and to provide evidences to further relevant studies.  Methods  From the Data and Information Management System for Integrated HIV/AIDS Prevention and Control of Chinese Center for Disease Control and Prevention, we extracted demographical, clinical and viral load (VL) detection data on all HIV/AIDS patients receiving ART at the age of more than 15 years in Yunnan province during the period from 2004 through 2018. The incidence of LLV among the HIV/AIDS patients with different ART regimens was analyzed statistically.  Results  Of the 93 944 HIV/AIDS patients included in the study, 21 203 (22.6%) were detected with LLV. Among the patients with LLV, 25% were detected with LLV at least two times; the most detected LLV level was 51 – 199 copies/mL, followed by 400 – 999 and 200 – 399 copies/mL; the once-only LLV was detected most frequently and the detection frequency decreased in turn for successive two times, discontinuous two times, successive several times, and discontinuous several times; the detected incidence of LLV was the highest during the first year of ART and the incidence declined yearly after the initiation of ART. During the retrospective observation period among the 76 736 HIV/AIDS patients receiving first-line ART, the detected frequency of 51 – 199 and 200 – 399 copies/mL LLV increased first, with the highest frequency in 2010, then declined, with the lowest frequency in 2016, and increased again; the detected frequency of 400 – 999 copies/mL LLV and virologic failure (VF) of ≥ 1 000 copies/mL decreased yearly before 2012 and then remained at a stable level. While among the 17 208 HIV/AIDS patients receiving second-line ART, the detected frequencies of the four levels of LLV mentioned above varied similarly, with a decreasing trend between 2008 – 2012 and a stabilization later after.  Conclusion  The detected incidence of LLV is relatively high among HIV/AIDS patients with different ART regimen in Yunnan province. The effect of LLV on outcomes of ART needs to be explored.
  • loading
  • [1]
    中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 国际流行病学传染病学杂志, 2018, 45(6): 361 – 378. doi: 10.3760/cma.j.issn.1673-4149.2018.06.001
    Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society – USA panel[J]. JAMA, 2016, 316(2): 191 – 210. doi: 10.1001/jama.2016.8900
    Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV[EB/OL]. [2020 – 10 – 15].
    European AIDS Clinical Society. European guidelines for treat-ment of hiv infected adults in Europe[EB/OL]. [2020 – 10 – 15].
    World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection[EB/OL]. [2020 – 10 – 15].
    Ping LH, Jabara CB, Rodrigo AG, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study[J]. PLoS One, 2013, 8(9): e71557. doi: 10.1371/journal.pone.0071557
    Cohen MS, Gamble T, McCauley M. Prevention of HIV transmission and the HPTN 052 study[J]. Annual Review of Medicine, 2020, 71: 347 – 360. doi: 10.1146/annurev-med-110918-034551
    Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy[J]. JAMA, 2016, 316(2): 171 – 181. doi: 10.1001/jama.2016.5148
    Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study[J]. The Lancet HIV, 2018, 5(8): E438 – E447. doi: 10.1016/S2352-3018(18)30132-2
    Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters[J]. The Journal of Infectious Diseases, 2009, 200(6): 984 – 990. doi: 10.1086/605446
    Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure[J]. Clinical Infectious Diseases, 2019, 69(12): 2145 – 2152. doi: 10.1093/cid/ciz129
    Elvstam O, Medstrand P, Yilmaz A, et al. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment[J]. PLoS One, 2017, 12(7): e0180761. doi: 10.1371/journal.pone.0180761
    Charuratananon S, Sungkanuparph S. Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy[J]. Journal of the International Association of Providers of AIDS Care (JIAPAC), 2015, 14(1): 12 – 16. doi: 10.1177/2325957414527168
    Elvstam O, Marrone G, Medstrand P, et al. All-cause mortality and serious non-AIDS events in adults with low-level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish nationwide observational study[J]. Clinical Infectious Diseases, 2020, doi: 10.1093/cid/ciaa413.
    中国疾病预防控制中心性病艾滋病预防控制中心. 国家免费艾滋病抗病毒药物治疗手册[M]. 4版. 北京: 人民卫生出版社, 2016.
    Zhang T, Ding HB, An MH, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort[J]. BMC Infectious Diseases, 2020, 20(1): 147. doi: 10.1186/s12879-020-4837-y
    云南省第三年防治艾滋病人民战争联合评估组. 云南省第三轮防治艾滋病人民战争评估报告[R]. 2016.
    The Antiretroviral Therapy Cohort Collaboration (ART-CC). Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients[J]. AIDS, 2015, 29(3): 373 – 383. doi: 10.1097/QAD.0000000000000544
    Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study[J]. The Lancet Infectious Diseases, 2018, 18(2): 188 – 197. doi: 10.1016/S1473-3099(17)30681-3
    国务院办公厅. 国务院办公厅关于印发中国遏制与防治艾滋病“十三五”行动计划的通知. 国办发〔2017〕8号)[EB/OL]. (2017 – 02 – 05).
    云南省人民政府. 关于印发《云南省第四轮防艾人民战争实施方案(2016 — 2020年)》的通知[R]. (云发[2016]17号), 2016.
    Fleming J, Mathews WC, Rutstein RM, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy[J]. AIDS, 2019, 33(13): 2005 – 2012. doi: 10.1097/QAD.0000000000002306
    Warren AM, Cheng AC, Watson K, et al. Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study[J]. Sexual Health, 2017, 14(3): 238 – 243. doi: 10.1071/SH16165
    Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study)[J]. Antiviral Therapy, 2015, 20(6): 655 – 660. doi: 10.3851/IMP2949
    Supervie V, Breban R. Brief report: per sex-act risk of hiv transmission under antiretroviral treatment: a data-driven approach[J]. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2018, 79(4): 440 – 444. doi: 10.1097/QAI.0000000000001845
    Yombi JC, Mertes H. Treatment as prevention for HIV infection: current data, challenges, and global perspectives[J]. AIDS Reviews, 2018, 20(3): 131 – 140.
    Iwuji CC, Shahmanesh M, Koole O, et al. Clinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care[J]. HIV Medicine, 2020, 21(7): 457 – 462. doi: 10.1111/hiv.12877
  • 加载中


    通讯作者: 陈斌,
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Article views (175) PDF downloads(30) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint